Chapter 16

Small Molecule FLT3 Tyrosine Kinase Inhibitors

Mark Levis and Donald Small

Abstract

<p>Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.</p>

Total Pages: 399-416 (18)

Purchase Chapter  Book Details

RELATED BOOKS

.Botanicals and Natural Bioactives: Prevention and Treatment of Diseases.
.Frontiers In Medicinal Chemistry.
.Alkaloids and Other Nitrogen-Containing Derivatives.
.Potential Health Benefits of Biologically Active Peptides Derived from Underutilized Grains: Recent Advances in their Isolation, Identification, Bioactivity and Molecular Analysis.